Bernard Leduc Selected Research

VEP protocol

4/2005

Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernard Leduc Research Topics

Disease

5	Breast Neoplasms (Breast Cancer) 08/2006 - 01/2002
2	Rectal Neoplasms (Rectal Cancer) 03/2011 - 10/2006
1	Neoplasms (Cancer) 03/2011
1	Neutropenia 03/2011
1	Diarrhea 03/2011
1	Adenocarcinoma 10/2006
1	Pathologic Complete Response 08/2006

Drug/Important Bio-Agent (IBA)

2	Leucovorin (Folinic Acid)FDA Link 03/2011 - 10/2006
2	Fluorouracil (Carac)FDA LinkGeneric 10/2006 - 03/2006
2	Vinorelbine (Navelbine)FDA LinkGeneric 04/2005 - 01/2002
2	Epirubicin (Ellence)FDA LinkGeneric 04/2005 - 01/2002
1	UracilIBA 03/2011
1	TegafurIBA 03/2011
1	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 03/2011
1	Docetaxel (Taxotere)FDA Link 08/2006
1	Pharmaceutical PreparationsIBA 08/2006
1	AnthracyclinesIBA 08/2006
1	Mitoxantrone (Novantrone)FDA LinkGeneric 03/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 04/2005
1	Methotrexate (Mexate)FDA LinkGeneric 01/2002

Therapy/Procedure

4	Radiotherapy 03/2011 - 12/2005
4	Neoadjuvant Therapy 08/2006 - 01/2002
3	Chemoradiotherapy 03/2011 - 03/2006
2	Drug Therapy (Chemotherapy) 04/2005 - 01/2002
1	Adjuvant Chemotherapy 03/2006
1	Adjuvant Chemoradiotherapy 03/2006
1	VEP protocol 04/2005